Brooke Enderle, PA
Physician Assistant · Wilmington, DENPI 1700461290
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 318 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$542
- Otsuka America Pharmaceutical, Inc.$534
- Astellas Pharma US Inc$417
- AstraZeneca$276
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,38297%
- Education$2173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $1,290 |
| Novo Nordisk | 73 | $1,221 |
| Lilly USA, LLC | 30 | $542 |
| Otsuka America Pharmaceutical, Inc. | 27 | $534 |
| Astellas Pharma US Inc | 15 | $417 |
| AstraZeneca | 9 | $276 |
| Indivior Inc. | 12 | $244 |
| GSK | 10 | $208 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $186 |
| Merck | 11 | $160 |
| Braeburn Inc. | 5 | $150 |
| Biohaven Pharmaceuticals, Inc. | 4 | $144 |
| ANI Pharmaceuticals, Inc. | 4 | $124 |
| Harmony Biosciences LLC | 4 | $118 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| Alkermes, Inc. | 5 | $99 |
| Pfizer | 5 | $94 |
| Bayer | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Medtronic | 4 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $70 |
| Abbott | 3 | $68 |
| Vanda Pharmaceuticals Inc. | 2 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Exact Sciences | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $26 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,599 in reported general payments places this provider in the 95th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 40 | $49,445 |
| JardianceEmpagliflozin | 25 | $36,157 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 215 | $35,044 |
| UbrelvyUbrogepant | 12 | $22,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $14,396 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,363 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $9,541 |
| LinzessLinaclotide | 11 | $5,855 |
| Omega-3 Acid Ethyl Esters | 13 | $1,707 |
| Atorvastatin Calcium | 131 | $1,454 |
| Levothyroxine Sodium | 114 | $1,340 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,300 |
| Gabapentin | 87 | $1,127 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,221 | $49,44540 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $208 | $36,35161 claims |
| Boehringer IngelheimJardiance | $18 | $36,15725 claims |
| AbbVieUbrelvy, Linzess | $1,290 | $28,62423 claims |
| AstraZenecaBreztri Aerosphere | $276 | $11,36314 claims |
| Indivior Inc.Suboxone | $244 | $9,54111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Wilmington
- Jason SaulWilmington$9K
- Matthew StumpWilmington$5K
- Christopher HoverWilmington$5K
- Julie SimsWilmington$5K
- Joan TaddeiWilmington$4K
- Gabriel PelaezWilmington$4K
- Caitlin McCarryWilmington$4K
- Samantha DelfeldWilmington$4K
- Shannon MohollenWilmington$4K
- Victoria SandlerWilmington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.